Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals

Applied Protein Technology Raises Hundreds of Millions in Series B Funding

Fineline Cube Aug 17, 2022

Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision...

Company Deals Drug

SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China

Fineline Cube Aug 17, 2022

SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment

Fineline Cube Aug 17, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Deals

Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion

Fineline Cube Aug 17, 2022

Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly...

Medical Device

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

Fineline Cube Aug 17, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...

Company

Sihuan Pharmaceutical Restructures with Dual Organization Model

Fineline Cube Aug 17, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...

Company Deals

Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China

Fineline Cube Aug 17, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...

Company Drug

Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention

Fineline Cube Aug 17, 2022

The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...

Company Deals

Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies

Fineline Cube Aug 17, 2022

Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly...

Company Drug

Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study

Fineline Cube Aug 17, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...

Company Drug

I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration

Fineline Cube Aug 17, 2022

China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...

Company Deals

Menovo Pharmaceutical Plans RMB892m Private Placement to Boost API Production

Fineline Cube Aug 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to raise up to...

Company Deals

BeiGene Partners with Ontada to Accelerate RWE Development in US Oncology Market

Fineline Cube Aug 17, 2022

China-based biotech company BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced that it has signed...

Company Drug

Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE

Fineline Cube Aug 17, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...

Company Drug

Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC

Fineline Cube Aug 16, 2022

Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...

Company Medical Device

Venus Medtech’s VenusP-Valve Used Again in US Compassionate Case

Fineline Cube Aug 16, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the second US market compassionate use of its...

Drug

Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review

Fineline Cube Aug 16, 2022

China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m

Fineline Cube Aug 16, 2022

US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...

Posts pagination

1 … 583 584 585 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.